Baseline law
Unauthorized possession, acquisition, cultivation, manufacture, supply, trade, import, and export involving controlled psilocybin or psilocin can be criminal offenses.
International law · reviewed July 22, 2026
Psilocybin in Germany: narrow compassionate-use program
Psilocybin and psilocin are listed as non-marketable narcotics under Germany’s Narcotics Act. A current BfArM-confirmed cohort compassionate-use program for treatment-resistant depression runs from June 18, 2026 through June 17, 2027. That named, time-limited program is not broad medical legalization or ordinary patient access.
Status in brief
What the current framework actually permits
Current medical exception
BfArM lists a cohort compassionate-use program for treatment-resistant depression led by the Central Institute of Mental Health for the stated 2026–2027 period.
Not ordinary access
The program does not create retail sales, general pharmacy access, routine prescribing, take-home products, personal use, or self-directed treatment.
Boundary
Research, compassionate use, and prescription access are different
Schedule I permits are exceptional and generally tied to scientific or other public-interest purposes. Clinical trials and compassionate use operate through separate approvals and named programs; neither makes psilocybin commercially available to the public.
Product-format context
Product descriptions, laboratory documentation, fulfillment policies, and client support remain on iMicrodosing.com. Deeper research remains on iMicrodosing.org.
Educational information only. Not medical advice. 21+ only.